M040 BODY FAT DISTRIBUTION AND ITS ASSOCIATED FACTORS IN KOREAN WOMEN WITH POLYCYSTIC OVARY SYNDROME

2012 ◽  
Vol 119 ◽  
pp. S544-S544
Author(s):  
C.H. Jin ◽  
J.-S. Yuk ◽  
K.-W. Yi ◽  
J.-H. Shin ◽  
T. Kim ◽  
...  
2015 ◽  
Vol 41 (10) ◽  
pp. 1577-1583 ◽  
Author(s):  
Chan Hee Jin ◽  
Jin Sung Yuk ◽  
Kyung Mook Choi ◽  
Kyung Wook Yi ◽  
Tak Kim ◽  
...  

2013 ◽  
Vol 20 (2) ◽  
pp. 107-115
Author(s):  
Cristian-Ioan Iuhas ◽  
Nicolae Costin ◽  
Cristina Niţă ◽  
Dan Mihu

AbstractBackground and Aims. Most women with Polycystic Ovary Syndrome (PCOS) are thought to have an abdominal body fat distribution, regardless of body mass index (BMI). The objective of our research was to compare body fat distribution between PCOS cases and BMI/age matched healthy control women. Materials and Methods. We compared 102 women with PCOS and 120 healthy female patients matched for age and BMI (retrospective review of the medical records). Visceral fat area (VFA) was measured by bioelectric impedance. Results. No significant differences were noted between the PCOS group and controls regarding total cholesterol, LDLcholesterol and triglycerides levels. Mean HDL-cholesterol concentration was significantly lower in the PCOS group (p=0.03). Mean fasting serum insulin and calculated HOMA-IR were higher in the PCOS group (14.2±7.2 vs. 9.1±4.1μU/mL, p<0.001, and 3.1±1.8 vs. 2.3±1.1, p=0.01 respectively). VFA was similar in patients with PCOS and in the control group. Conclusions. Obese women with PCOS have no preponderant accumulation of visceral fat, compared with weight/age-matched controls. Our data suggest that the distribution of fat to visceral depots is unlikely to be the entire explanation for the metabolic abnormalities observed in women with PCOS.


1995 ◽  
Vol 86 (4) ◽  
pp. 516-519 ◽  
Author(s):  
T DOUCHI ◽  
H HUIN ◽  
S NAKAMURA ◽  
T OKI ◽  
S YAMAMOTO ◽  
...  

2021 ◽  
Vol 12 ◽  
Author(s):  
Shiqin Zhu ◽  
Zeyan Li ◽  
Cuiping Hu ◽  
Fengxuan Sun ◽  
Chunling Wang ◽  
...  

BackgroundWomen with polycystic ovary syndrome (PCOS) are generally considered to be central obese and at higher risks of metabolic disturbances. Imaging methods are the golden standards for detecting body fat distribution. However, evidence based on magnetic resonance imaging (MRI) and computed tomography (CT) is conflicting. This study systematically reviewed the imaging-based body fat distribution in PCOS patients and quantitatively evaluated the difference in body fat distribution between PCOS and BMI-matched controls.MethodsPUBMED, EMBASE, and Web of Science were searched up to December 2019, and studies quantitatively compared body fat distribution by MRI, CT, ultrasound, or X-ray absorptiometry (DXA) between women with PCOS and their BMI-matched controls were included. Two researchers independently reviewed the articles, extract data and evaluated the study quality based on Newcastle-Ottawa Scale (NOS).Results47 studies were included in systematic review and 39 were eligible for meta-analysis. Compared to BMI-matched controls, higher accumulations of visceral fat (SMD 0.41; 95%CI: 0.23-0.59), abdominal subcutaneous fat (SMD 0.31; 95%CI: 0.20-0.41), total body fat (SMD 0.19; 95% CI: 0.06-0.32), trunk fat (SMD 0.47; 95% CI: 0.17-0.77), and android fat (SMD 0. 36; 95% CI: 0.06-0.66) were identified in PCOS group. However, no significant difference was identified in all the above outcomes in subgroups only including studies using golden standards MRI or CT to evaluate body fat distribution (SMD 0.19; 95%CI: -0.04-0.41 for visceral fat; SMD 0.15; 95%CI: -0.01-0.31 for abdominal subcutaneous fat). Moreover, meta-regression and subgroup analyses showed that young and non-obese patients were more likely to accumulate android fat.ConclusionsPCOS women seem to have abdominal fat accumulation when compared with BMI-matched controls. However, MRI- and CT- assessed fat distribution was similar between PCOS and controls, suggesting central obesity may be independent of PCOS. These findings will help us reappraise the relationship between PCOS and abnormal fat deposition and develop specialized lifestyle interventions for PCOS patients.Systematic Review RegistrationPROSPERO, identifier CRD42018102983.


Sign in / Sign up

Export Citation Format

Share Document